Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Breast Cancer Metastatic Clinical Trial

— ROGABREAST  

Official title:

Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04483505
• Other study ID #: ROGABREAST
• Secondary ID: 2020-000055-12
• Status: Completed
• Phase: Phase 1
• Start date: November 25, 2020
• Est. completion date: April 4, 2023

Study information

• Verified date: December 2023
• Source: Fundacion CRIS de Investigación para Vencer el Cáncer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib, according RECIST 1.1 criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: April 4, 2023
• Est. primary completion date: April 4, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Women =18 years-old.

2. Diagnostic of metastatic or locally advanced non-resectable breast cancer.

3. Ability to understand and signing of the PIS/ICF for FGFR testing. FGFR testing will be performed centrally at CNIO (RNAscope and FISH).

4. Ability to understand and signing the written PIS/ICF for study treatment eligibility.

5. Availability of fresh tumor biopsy specimen for FGFR1/3 mRNA expression and FISH testing.

6. Hormone-receptor positivity defined by at least 5% positivity of ER and/or PR (no central laboratory testing is required).

7. Positivity of FGFR1/2/3 by RNA-scope and/or FISH.

8. Patients must have undergone a previous hormonal treatment line for metastatic disease, with anastrozole, letrozole or exemestane, plus a cell cycle inhibitor (palbociclib, ribociclib or abemaciclib).

9. Recovery of toxicities from previous regimens to equal or below tolerable grade II.

10. HER2-negativity (Herceptest 0+, 1+ or 2+ with negative FISH/CISH/SISH).

11. ECOG performance status of 0/1.

12. Life expectancy of >24 weeks.

13. Adequate bone marrow, liver and renal function as assessed by laboratory requirements:

1. Absolute neutrophil count (ANC) = 1,500/mm3

2. Hemoglobin = 10 g/dL (without transfusion or erythropoietin .

3. Platelet count = 100,000/mm3

4. Total bilirubin = 1.5 × the upper limit of normal (ULN).

5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN

6. Alkaline phosphatase = 2.5 times ULN

7. Lipase and amylase = 2 × ULN.

8. Serum albumin = 2.5 g/dl.

9. Glomerular filtration rate (GFR) = 60 mL/min/1.73 m2

14. INR = 1.5 × ULN and PTT or activated PTT (aPTT) = 1.5 × ULN.

15. Negative serum pregnancy test in women of childbearing potential.

16. Women of reproductive potential must agree to use highly effective contraception when sexually active.

17. Evaluable disease according to RECIST 1.1 criteria.

Exclusion Criteria:

1. Involvement in the planning and/or conduct the study.

2. Previous enrollment in the present study.

3. Previous or concurrent cancer except:

1. Cervical carcinoma in situ.

2. Treated basal-cell carcinoma or squamous cell skin cancer.

3. Any other cancer curatively treated > 3 years before the first study drug administration.

4. Receipt the last dose of anticancer therapy at least 21 days prior to the first dose of study drug.

5. Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized completely

6. Anti-cancer therapy is defined as any agent or combination of agents with clinically proven anti-tumor activity

7. Previous treatment with anti-FGFR directed therapies.

8. Irradiation of single bony lesions with risk of fracture. Zoledronic acid or denosumab started prior to trial registration is allowed.

9. Symptomatic metastatic brain or meningeal tumors.

10. History or current condition of an uncontrolled cardiovascular disease including any

of the following conditions:

1. Congestive heart failure, unstable angina (symptoms of angina at rest) or

2. New-onset angina

3. Myocardial infarction (MI).

4. Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.

5. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, must be on a stable medical regimen.

11. Known human immunodeficiency virus (HIV) infection.

12. Active hepatitis B virus or hepatitis C infection requiring treatment.

1. Patients with past HBV infection or resolved HBV infection are eligible if HBV DNA is negative.

2. Patients positive for hepatitis C virus are eligible only if polymerase chain reaction is negative for HCV RNA.

13. Any condition that in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results, or inability to comply with the study and follow-up procedures.

14. Previous or concomitant participation in another clinical study with investigational medicinal products.

15. Active tuberculosis.

16. Clinically active infections.

17. Treatment with therapeutic oral or i.v. antibiotics.

18. Patients receiving prophylactic antibiotics are eligible.

19. Seizure disorder requiring medication.

20. History of organ allograft.

21. Evidence or history of bleeding diathesis or coagulopathy.

22. Any hemorrhage / bleeding event CTCAE v.5.0 = Grade 3.

23. Serious, non-healing wound, ulcer or bone fracture.

24. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.

25. Any malabsorption condition.

26. Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.

27. Peripheral sensory neuropathy of CTCAE v.5.0 Grade 2 or higher.

28. Current evidence of endocrine alteration of calcium phosphate homeostasis.

29. Concomitant therapies that are known to increase serum phosphate levels.

30. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.

31. Breast-feeding.

32. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4.

33. Autologous bone marrow transplant or stem cell rescue.

34. Major surgery, open biopsy or significant traumatic injury.

35. Renal failure requiring peritoneal dialysis or hemodialysis.

36. Systolic/diastolic blood pressure = 100/60 mmHg and concurrent heart rate = 100/min.

37. Inability to swallow oral tablets.

38. Close affiliation with the investigational site; e.g. a close relative of the investigator or a dependent person.

39. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.

40. Arterial or venous thrombotic events or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism.

Related Conditions & MeSH terms

• Breast Cancer Metastatic
• Breast Neoplasms
• Hormone Receptor Positive Malignant Neoplasm of Breast
• Neoplasms

Intervention

Drug:
• Combination, Rogaratinib + palbociclib + fulvestrant
Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days. Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows: Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients). Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients). Treatment will continue until disease progression.

Locations

Country	Name	City	State
Spain	Hospital Universitario de Fuenlabrada	Fuenlabrada	Madrid
Spain	Institut Català d'oncologia - Hospital Duran I Reynals	Hospitalet de Llobregat	Barcelona
Spain	Hospital Universitari Arnau de Vilanova de Lleida	Lleida
Spain	Hospital Clinico San Carlos	Madrid
Spain	Hospital Ramon y Cajal	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Quirónsalud Madrid	Pozuelo De Alarcón	Madrid
Spain	Hospital Clínico Universitario de Valencia	Valencia

Sponsors (4)

Lead Sponsor	Collaborator
Fundacion CRIS de Investigación para Vencer el Cáncer	Apices Soluciones S.L., Bayer, Pfizer

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended Phase 2 Dose	Highest dose at which <1 out of 6 patients experience a DLT.	2 months
Primary	Incidence of Treatment-Emergent Adverse Event	Percentage of patients with each adverse event.	2 years
Secondary	Progression free survival	Time from the date of first dose of study treatment to the date of progression or death (from any cause).	2 years
Secondary	Pharmacokinetic interactions of fulvestrant and palbociclib over rogaratinib metabolism.	Plasmatic levels of fulvestrant, palbociclib and rogaratinib	2 years
Secondary	Pharmacodynamic markers levels of FGFR1 Blockade	Plasma levels of phosphate and FGF23.	2 years
Secondary	Response rate	Percentage of patients that achieve response according to RECIST 1.1 criteria.	1 year